Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07215702 | A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | PHASE2 | RECRUITING | 124 | — | — | Feb 10, 2026 | Feb 11, 2027 | May 5, 2026 | 71 | United States, Argentina +12 |
The total area under the curve for 24-hour creatinine clearance measured throughout the treatment period.
| Arm | Type | Description |
|---|---|---|
| Arm 1 (AZD4144) | EXPERIMENTAL | AZD4144 solution for IV infusion |
| Arm 2 (Placebo) | PLACEBO_COMPARATOR | Placebo concentrate for solution for infusion |
| Name | Type | Description |
|---|---|---|
| AZD4144 | DRUG | Intravenous solution of AZD4144 will be administered to randomised participants according to the treatment arm to which they have been assigned. |
| Placebo | DRUG | Intravenous solution of Placebo will be administered to randomised participants according to the treatment arm to which they have been assigned. |
Inclusion Criteria Age ≥ 18 to ≤ 80 years at the time of signing the informed consent. Participants who are admitted to an ICU or an equivalent critical-care unit. Diagnosis of sepsis according to criteria defined by The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| ImmunityBio Inc | IBRX | 1 | PHASE2 | Nogapendekin alfa inbakicept |
| Bluejay Diagnostics, Inc. | BJDX | 2 | — | Undisclosed |
| CytoSorbents Corporation | CTSO | 1 | — | Undisclosed |
| Danaher Corporation | DHR | 3 | — | Undisclosed |
| Spectral AI, Inc. Class A | MDAI | 1 | NA | Undisclosed |